Evidence map›Paper›PMID 39585516›Full record

Trial reportInternational journal of clinical oncology2025

Differences in efficacy of biweekly irinotecan plus cisplatin versus irinotecan alone in second-line treatment of advanced gastric cancer with or without prior gastrectomy.

Kazuhiro Nishikawa, Wasaburo Koizumi, Akira Tsuburaya, Motoko Suzuki, Satoshi Morita, Kazumasa Fujitani, Yusuke Akamaru, Ken Shimada, Hisashi Hosaka, Ken Nishimura and 3 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kazuhiro NishikawaCancer Treatment Center, Osaka International Medical & Science Center, Osaka Keisatsu Hospital, 10-31 Kitayama-cho, Tennoji-ku, Osaka, 543-0035, Japan. kazuno13@hotmail.co.jp.ORCID http://orcid.org/0000-0003-1213-2732
Wasaburo KoizumiKitasato University, 1-15-3, Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
Akira TsuburayaDepartment of Surgery, AOI Nanasawa Rehabilitation Hospital, Atsugi, Japan.
Motoko SuzukiDepartment of Data Science, National Cancer Center Hospital East, Chiba, Japan.
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, 54, Shogoinkawaharacho, Sakyo-ku, Kyoto, 606-8397, Japan.
Kazumasa FujitaniDepartment of Surgery, Osaka General Medical Center, 3-1-56, Bandaihigashi,Sumiyoshi-ku, Osaka, 558-0056, Japan.
Yusuke AkamaruDepartment of Surgery, Osaka Rosai Hospital, 1179-3 Nagasonecho, Kita-ku, Sakai City, Osaka, 591-8025, Japan.
Ken ShimadaDepartment of Internal Medicine, Division of Medical Oncology, Showa University Koto Toyosu Hospital, 5-1-38 Toyosu, Koto-ku, Tokyo, 135-8577, Japan.
Hisashi HosakaDepartment of Gastroenterology, Gunma Prefectural Cancer Center, 617-1, Takahayashinishi-cho, Ohta, 373-0828, Japan.
Ken NishimuraDepartment of Oncology, Kitasato University Kitasato Institute Hospital, 5-9-1, Shirokane, Minato-ku, Tokyo, 108-8642, Japan.
Takaki YoshikawaDepartment of Gastric Surgery, The National Hospital Organization National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Toshimasa TsujinakaIzumi City General Hospital, 4-5-1, Wakecho, Izumi, Osaka, 594-0073, Japan.
Junichi SakamotoTokai Central Hospital, 4-6-2, Sohara Higashijimacho, Kakamigahara, 504-8601, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiweekly irinotecan plus cisplatin combination therapy (BIRIP) and irinotecan monotherapy (IRI) are both expectable second-line chemotherapy (SLC) options for treating advanced gastric cancer (AGC). Although many patients receiving SLC have undergone gastrectomy, the impact of gastrectomy on SLC remains unclear, and the impact of gastrectomy may vary from regimen to regimen. PATIENTS AND

methodsA total of 290 eligible patients registered in two randomized phase III trials evaluating BIRIP (IRI, 60 mg/m

resultsThe BIRIP demonstrated significantly longer OS (11.1 vs. 6.8 months; HR 0.64; P = 0.026) and PFS (3.7 vs. 2.3 months; HR 0.54; P = 0.003) than the IRI, as well as better ORR (23.5% vs. 7.1%, P = 0.046) and DCR (74.5% vs. 47.6%, P = 0.010) in NGG. Although in PGG, the BIRIP failed to demonstrate differences in OS (13.8 vs. 13.8 months; HR 0.94; P = 0.722), PFS (4.9 vs. 4.5 months; HR 0.82; P = 0.194), ORR (18.3% vs. 20.5%) and DCR (70.4% vs. 65.1%). The incidence of grade 3 or worse adverse events did not differ except for a high incidence of anemia in the BIRIP group in PGG.

conclusionsBIRIP was an effective treatment option that may improve survival outcomes among patients with AGC without previous gastrectomy. CLINICAL

trial registrationUMIN000025367.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsIrinotecanStomach NeoplasmsAdultAgedCisplatinFemaleGastrectomyHumansMaleMiddle AgedTreatment OutcomeCisplatinIrinotecanAdvanced gastric cancerBiweekly irinotecan plus cisplatinGastrectomyIrinotecanSecond-line chemotherapy

Identifiers

PMID39585516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.